Desafios e oportunidades em ética clínica com a implementação do Ato de Fim-da-Vida na Córeia by Junga Kim, Claire
 177
Acta Bioethica  2019; 25 (2): 177-186
CHALLENGES AND OPPORTUNITIES IN CLINICAL ETHICS 
WITH THE IMPLEMENTATION OF KOREA’S END!OF!LIFE ACT 
Claire Junga Kim1
Abstract: !is paper examines the possible impacts of the Act on Decisions on Life-Sustaining Treatment for Patients in 
Hospice and Palliative Care or at the End of Life in Korea (Korea’s end-of-life act), legislated in 2016, on the development 
of hospital ethics committees and clinical ethics consultation services in South Korea. Clinical ethics in Korea has not made 
much progress in comparison to other subdisciplines of biomedical ethics. While the enactment of this law may give rise to 
beneficial clinical ethics services, it is possible that customary practices and traditional authorities in Korean society will come 
into conflict with the norms of clinical ethics. !is paper examines how the three main agents of Korean society—family, 
government, and medical professionals—may clash with end-of-life stage norms in clinical ethics, thus posing obstacles to the 
development of hospital committees and consultation services. A brief outline of what lies ahead for the progress of clinical 
ethics practice is explored.
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Desafíos y oportunidades en ética clínica con la implementación de la Ley de fin de vida de Corea
Resumen: Este documento examina los posibles impactos de la Ley de decisiones sobre el tratamiento de soporte vital para 
pacientes en hospicios y cuidados paliativos, o al final de la vida en Corea (Ley de Corea del Final de la Vida), legislada en 
2016, sobre el desarrollo de comités de ética hospitalaria y servicios de consulta de ética clínica en Corea del Sur. La ética 
clínica en Corea no ha avanzado mucho en comparación con otras subdisciplinas de la ética biomédica. Si bien la promulgación 
de esta ley puede dar lugar a servicios de ética clínica beneficiosos, es posible que las prácticas tradicionales y las autoridades 
tradicionales en la sociedad coreana entren en conflicto con las normas de ética clínica. Este documento examina cómo los 
tres agentes principales de la sociedad coreana —familia, gobierno y profesionales médicos— pueden chocar con las normas 
de ética clínica al final de la vida, lo que plantea obstáculos para el desarrollo de comités hospitalarios y servicios de consulta. 
Se explora un breve resumen de lo que queda por delante para el progreso de la práctica de la ética clínica.
Palabras clave: ética clínica, comité de ética del hospital, consulta de ética, tratamiento de soporte vital, atención al final de 
la vida, autodeterminación
Desafios e oportunidades em ética clínica com a implementação do Ato de Fim-da-Vida na Córeia
Resumo: Este artigo examina os possíveis impactos que o Ato sobre Decisões Relacionadas a Tratamento de Manutenção da 
Vida para Pacientes em Casas de Idosos e de Cuidados Paliativos ou ao Fim da Vida na Coréia (ato de fim da vida da Coréia), 
aprovado pelo legislativo em 2016, sobre o desenvolvimento de comitês de ética de hospitais e serviços de consulta sobre 
ética clínica na Coréia do Sul. Ética clínica na Coréia não sofreu muito progresso em comparação com outras subdisciplinas 
da ética biomédica. Enquanto a promulgação desta lei pode dar origem a serviços de ética clínica proveitosos, é possível que 
práticas usuais e autoridades tradicionais na sociedade coreana entrarão em conflito com as normas da ética clínica. Este artigo 
examina como os três principais agentes da sociedade coreana – família, governo e profissionais médicos – podem se chocar 
com normas de estágios de fim da vida em ética clínica, colocando assim obstáculos para o desenvolvimento de comitês hospi-
talares e serviços de consulta. Um breve esboço do que vem pela frente para o progresso da prática de ética clínica é explorado.
Palavras chave: ética clínica, comitê de ética hospitalar, consulta ética, tratamento de manutenção da vida, cuidados de fim 
da vida, autodeterminação
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rectly related to patient care. !e purpose of this 
paper is to explore challenges and opportunities 
as the establishment of ethics committees and 
consultation services—common types of clinical 
ethics in practice—emerges in Korea. 
Similar to the history of modern biomedical ethics 
in many other countries, the practice of biomed-
ical ethics in Korea has developed rapidly over a 
short period of time. As for education aspects of 
biomedical ethics, although the field was initial-
ly introduced in few medical schools for future 
doctors in the late 1980s(3), it has now become 
part of the common curricula in Korean medical 
schools, and is covered in medical licensing exams 
for doctors. Graduate schools are also providing 
relevant programs. Research aspects of biomedical 
ethics began to emerge with the foundation of the 
Korean Society for Medical Ethics in 1997(4) and 
the Korean Bioethics Association in the follow-
ing year(5). !ese have led meaningful academ-
ic discussions by way of published discourse in 
academic journals. !e Korea National Institute 
for Bioethics Policy(6), along with many medical 
schools that conduct biomedical ethics research, 
publish frequently on the topic in their journals 
and actively participate in academic discussions. 
!e practice of biomedical ethics has been posi-
tively impacted by the abovementioned progress 
made in the academic world, which has led to the 
establishment of institutions and laws related to 
bioethics. In 2005, South Korea’s Bioethics and 
Safety Act was legislated(7), a bill on the rights 
of human research subjects, on genetics, and on 
embryo-related research. A department was es-
tablished at the Ministry of Health and Welfare 
to address bioethics-related issues. !e National 
Bioethics Committee(8) was established together 
with the Korea National Institute for Bioethics 
Policy, a foundation to support the committee. 
Additional to all these initiatives, many institu-
tions and laws related to new bioethics issues, in-
cluding clinical trials for medicines and medical 
devices, have been introduced. Needless to say, it 
is the bioethics scholars who have made signifi-
cant contributions to this dimension of progress 
in biomedical ethics. Among many areas of bio-
ethics in practice, rapid progress has been made 
in the field of research ethics in particular. With 
institutional review boards (IRBs) established in 
Introduction
In 2016, the Act on Decisions on Life-Sustaining 
Treatment for Patients in Hospice and Palliative 
Care or at the End of Life (hereafter the Act)(1) 
was signed. !e Act is a law concerning the with-
holding and withdrawing of life-sustaining treat-
ments for patients at the end of life. It serves as 
an opportunity to promote the practice of clinical 
ethics in the form of hospital ethics committees 
or clinical ethics consultation services. !is is be-
cause the law clearly recognizes patients’ rights 
to self-determination concerning life-sustaining 
treatment, it mandates the establishment of insti-
tutions for clinical ethics practice, and therefore, 
it facilitates public discussion and policy devel-
opment related to clinical ethics issues. To date, 
education and research aspects of biomedical 
ethics have made great progress in Korea, as has 
the practice of research ethics. Nevertheless, the 
practice of clinical ethics in hospitals has not been 
well developed to date, and services to jointly dis-
cuss and address ethical issues are still lacking. 
!erefore, it is meaningful to investigate whether 
enactment and enforcement of the Act have the 
potential to lead to successful implementation of 
clinical ethics committees and consultation ser-
vices. !is paper attempts to examine the possi-
bility of the practice of clinical ethics flourishing 
in Korea and to identify potential obstacles that 
may prevent such success. Potential obstacles in-
clude the risks of customary practices in Korea 
conflicting with biomedical ethics, which is an 
imported discipline. In particular, this paper in-
vestigates how family, government, and medical 
professionals —three tenets of authority in Kore-
an society— may emerge as obstacles to the prac-
tice of clinical ethics.
Development of Biomedical Ethics in Korea
!e groundwork for the practice of clinical ethics 
in Korea has been laid with the enactment and 
enforcement of the Act. !is paper follows the 
definition of clinical ethics according to Singer, 
Pelleggrino, and Siegler, as having a goal “to im-
prove the quality of patient care by identifying, 
analyzing, and attempting to resolve the ethical 
problems that arise in practice(2).” !erefore, as a 
subdiscipline of biomedical ethics, clinical ethics 
comprises research, education, and practice di-
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the law. !erefore, the Act paved the way for clin-
ical ethics, once limited to areas of research and 
education, to be extended to real-world practices 
in healthcare. 
Korea’s End-of-life Act and Further Opportu-
nities
!e Act, legislated in February 2016, covers hos-
pice and palliative care, as well as decisions on 
life-sustaining treatment. Articles on hospice and 
palliative care were enforced 18 months after the 
enactment of the law and articles on decisions 
on life-sustaining treatment came into e"ect two 
years after enactment. Hospice and palliative 
care-related content in the Act mainly serves to 
promote related fields, while content on deci-
sions about life-sustaining treatment in the law 
explicates the extent of patients’ rights to forego 
life-sustaining treatment, the means thereof, and 
the obligations of medical professionals, medical 
institutions, and the nation to help patients re-
alize their rights. Hence, the Act, especially the 
articles pertaining to decisions on life-sustaining 
treatment, is closely linked to clinical ethics. Le-
gal content including an advance statement on 
life-sustaining treatment and a life-sustaining 
treatment plan, each more or less corresponding 
to practices of advance directives and Physician 
Orders for Life-Sustaining Treatment (POLST) 
in the US, is provided in the Act, whereby pa-
tients’ stated intentions to withhold or withdraw 
life-sustaining treatments are indicated. However, 
advance statements on life-sustaining treatment 
are di"erent from advance directives insofar as 
advance statements exclude the element of du-
rable power of attorney. In addition, legal doc-
uments in the Act only allow patients to opt out 
of life-sustaining treatments that are designated 
by the law, as opposed to allowing them to pro-
vide value history or to indicate their wishes in 
an open-ended blank space. Presently, the term 
“life-sustaining treatment” is defined in the Act 
as a “medical treatment by cardiopulmonary re-
suscitation, hemodialysis, administering antican-
cer drugs, mechanical ventilation and any other 
treatment prescribed by Presidential Decree to a 
patient at the end of life, which merely extend the 
duration of the end-of-life process without cura-
tive e"ect(1).” !e definition of “life-sustaining 
treatment” which patients can opt out of accord-
the majority of hospitals and universities, research 
ethics education has been provided to researchers, 
and a consensus in research ethics has been built 
through peer reviews. !e number of trained as-
sistant sta", such as assistant administrators, has 
increased as well. Nevertheless, the practice of 
clinical ethics has shown insignificant progress in 
comparison to accomplishments in research and 
education aspects of biomedical ethics, and like-
wise, insu#cient progress in comparison to ac-
complishments in the practice of research ethics, 
which is a subdiscipline of biomedical ethics. 
Among many activities that deal with ethical is-
sues related to bedside patient care, this paper is 
particularly concerned with the establishment of 
ethics committees and consultation services, the 
role of which is to address and discuss pertinent 
issues and suggest the best possible solutions to 
problems. !is is not to say that the goal of an 
ethics committee or consultation service in deal-
ing with such ethical issues is merely to seek reso-
lution, thereby ignoring the process of identifying 
and analyzing the problems. Nor do we disregard 
the possibility of having independent healthcare 
professionals who are su#ciently competent to 
identify and appropriately deal with any ethical is-
sues they may face, even in the absence of formal-
ized institutions or processes such as a committee 
or consultation service. Nevertheless, it is safe to 
presume that when clinical ethics consultation 
services are standardized across hospitals, as long 
as the usefulness of the practice is undeniable, a 
culture will be fostered among healthcare pro-
fessionals wherein clinical ethics are valued and 
ethics-related issues are addressed with systematic 
e"orts. Viewed in this light, the practice of clin-
ical ethics has yet to reach an advanced stage in 
Korea. Ethics-based services provided by individ-
ual consultants are few, and ethics committees are 
installed in hospitals only nominally. Until a few 
years ago, the number of annual meetings held 
by hospital ethics committees in hospitals aver-
aged 2(9), which is a small number. Many of the 
committees were paper committees, operating in 
name only. Under these circumstances, Korea’s 
end-of-life act was legislated, mandating that 
hospitals that provide life-sustaining treatments 
must install ethics committees, known as health-
care institution ethics committees according to 
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Second, the Act requires establishment of an o#-
cial body for the practice of clinical ethics. Article 
14 says that “a medical institution that intends to 
perform the services concerning [the] withdraw-
ing and withholding of life-sustaining treatment 
shall establish a healthcare institution ethics com-
mittee(1).” Healthcare institution ethics commit-
tees are required by law to perform activities such 
as deliberation, counseling, and education, there-
by making them analogous to hospital ethics com-
mittees (HECs), with an exclusive focus on cases 
related to life-sustaining treatment. As of March 
2019, 174 medical institutions have installed 
healthcare institution ethics committees(13), 
a trend that is similar to what happened in the 
history of Korea’s research ethics field. When the 
Bioethics and Safety Act(7) required institutions 
to establish institutional review boards (IRBs), 
it prompted hospitals, and subsequently univer-
sities, to secure relevant services and human re-
sources. Certainly the rapid progress in the field 
of research ethics was partly attributable to legal 
requirements from the Bioethics and Safety Act. 
!us we can expect that explicit requirements in 
the Act concerning the establishment of health-
care institution ethics committees are likely to 
lead to identifying, analyzing, and resolving ethi-
cal issues related to life-sustaining treatments. In 
turn, these advancements will stand to serve as 
a foundation for dealing with a greater scope of 
ethical issues that arise in bedside patient care, 
not being limited to ethical issues around life-sus-
taining treatment. 
!ird, by strengthening people’s recognition of 
their rights to self-determination at the end of 
life and accelerating the establishment of health-
care institution ethics committees, the Act has 
generated discourse and publicized clinical ethics 
issues, and has facilitated relevant policy devel-
opment, including amendment of the Act. More 
discussion than ever before has occurred concern-
ing people’s end-of-life decisions. Not only the 
implications and e"ectiveness of the Act, but also 
limitations and shortcomings in the application 
of the law have been reflected upon and analyzed 
from both within and outside of the medical 
profession. !is type of engagement allows tacit 
assumptions, which had been previously accept-
ed without questioning, to be tested and further 
ing to the Act is highly rigid, specifically stating 
the purpose and nature of treatment, as well as 
treatment type and timing of treatment, setting 
a time frame as the end-of life process. !e term 
“end-of-life process” is also strictly defined as a 
stage closer to imminent death, distinct from the 
“terminal stage” of a patient’s life, which could 
last months before the patient’s death. From a 
logical point of view, the Act is interpreted to 
mean that life-sustaining treatments to extend the 
duration of life during the terminal stage must be 
maintained, and that such treatments may only 
be withheld or withdrawn from patients when 
they enter the end-of-life process. Moreover, in 
cases of artificial nutrition, hydration, and sim-
ple oxygen, these treatments may not be withheld 
or withdrawn at any time because the Act rec-
ognizes patients’ rights to self-determination to a 
limited extent only. Nonetheless, despite the Act’s 
limitations, it is clear that the law does provide a 
landmark opportunity for clinical ethics in Korea, 
particularly for the practice of clinical ethics.
First, the Act is the inaugural law in Korea stat-
ing the rights of patients to self-determination 
in decisions on life-sustaining treatment, despite 
limiting the scope of life-sustaining treatment to 
patients at the end-of-life only. Previous court 
rulings had established that the right to making 
decisions on medical treatment belonged to the 
patient alone, and not anyone else(10,11). In ad-
dition, other rulings have indicated that decisions 
on life-sustaining treatment for incompetent pa-
tients could be made based on wishes previously 
stated by the patient before he or she had become 
incompetent(12). Before enforcement of the Act, 
however, no law existed to declare the extent of 
patients’ rights to self-determination, to speci-
fy legal documents for patients to realize their 
rights, and to prescribe the obligations of med-
ical professionals to carry out the withholding or 
withdrawal of life-sustaining treatments. !ere is 
no doubt that the Act clearly enhances people’s 
recognition of their rights around life-sustaining 
treatments. In addition, insofar as the Act com-
pels medical professionals to understand and 
agree to the rights of patients to self-determina-
tion at the end of life, it can be said that the law 
has caused medical professionals to adopt an im-
portant premise for the practice of clinical ethics. 
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what the Act can realistically do. 
Challenges in the Future of Clinical Ethics
When predicting the impact of the Act, it must 
be considered that biomedical ethics is an “im-
ported discipline” in Korea. While the history of 
biomedical ethics traces back to the long tradition 
of healing practices or the history of the healing 
profession itself, the modern meaning of biomed-
ical ethics emerged in the late 1960s in the US, 
thereafter becoming formalized as an academic 
field(17). Accordingly, in many countries, includ-
ing Korea, biomedical ethics is not an indigenous 
discipline, but rather an imported one in which 
already advanced theories are introduced in aca-
demic settings and taught to succeeding genera-
tions. !is implies that the nature of the tenets 
of an imported discipline, in terms of its concep-
tions of individuals and society, may di"er from 
those of a native culture and native institutions. 
For instance, it has been continuously pointed 
out that the conception of individualistic auton-
omy is a central premise of Western biomedical 
ethics, but is not central in non-Western civiliza-
tions(18,19,20). As issues arising in clinical ethics 
are closely intertwined with our real lives, a clash 
between aspects of the imported discipline and 
our customary practices will inevitably emerge. 
Situations involving clinical ethical issues are 
very specific—indeed, inseparable—to human 
lives insofar as the discipline deals with patient 
care wherein sick people are being looked after 
by others. !erefore, not surprisingly, these situ-
ations intersect with certain customary practices, 
regulations, and power structures of Korean soci-
ety. Conversely, there are also extensive custom-
ary practices, regulations, and power structures 
specific to medical practices in Korea, which 
recur in our daily lives as second nature, all of 
them inextricably entwined with historic and so-
ciopolitical factors. For instance, treatment deci-
sions for elderly patients are frequently a"ected 
by di"erent sets of roles and the status of patients’ 
adult-age children based on gender. Also, doctors’ 
tendencies toward medical overtreatment can be 
attributed to the existence of criminal status for 
the assisting of suicide under Korea’s criminal law. 
!erefore, these tacit norms specific to Korea may 
collide with the practice of clinical ethics insofar 
as clinical ethics, among all the other subdisci-
challenged. Such assumptions include people’s 
definitions of what is a good death, of maintain-
ing dignity at the end-of-life, the role of govern-
ment, medical professionals, and families, and 
patients’ rights. Practices that were once carried 
out without any special consideration, such as 
treating patients at terminal stages according to 
the wishes of patients’ families without inform-
ing patients of their health status, have now been 
brought to light to be scrutinized in terms of le-
gality and ethicality. 
Consequently, will enforcement of the Act cause 
the practice of clinical ethics to thrive in Korea? 
Just as the practice of research ethics has become 
an everyday protocol with the institutionalization 
of IRBs, does the practice of clinical ethics con-
sultation have the potential to take root in the 
daily lives of patients and their families? What is 
more, does the future workforce in the practice 
of clinical ethics have the potential to be profes-
sionalized, as in the case of the United States? In 
the US, certification programs for ethics con-
sultation services are now being established by 
academic society(14). !e professionalization 
of clinical ethics practice in the US took place 
within thirty years following the enactment of 
the Patient Self Determination Act in 1990(15), 
which o#cialized patients’ rights to self-determi-
nation in healthcare decisions. In 1991, the Joint 
Commission on Accreditation of Healthcare 
Organizations called for a “mechanism” for “the 
consideration of ethical issues arising in the care 
of patients(16).” During the preparatory stage 
for enforcement of the Act, and ongoing in the 
early stages of enforcement, scholars of biomed-
ical ethics are working to sketch out prospects, 
as well as determine possible leading consultation 
types of clinical ethics practice in Korea, while 
also expressing an urgent need for manpower and 
resources in the field. !ere are mixed outlooks, 
some rosy and some gloomy. Acknowledging that 
the author holds a biased view, not free from the 
influence of personal inclination and social posi-
tion, this paper aims to analyze in the most ob-
jective way possible the impact of the new set of 
circumstances caused by the Act on the practice 
of clinical ethics in Korea. Insofar as the possible 
positive outcomes of the Act have already been 
explored, we turn now to limitations in terms of 
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the practice of clinical ethics to be established in 
Korea, an honest examination of the current state 
of a"airs is needed and endeavors toward required 
changes are imperative. !is paper does not in-
tend to highlight a pessimistic scenario wherein 
the future practice of clinical ethics fails in Ko-
rea. Rather, it intends to lay the groundwork for 
further discussion based on accurate recognition 
of possible challenges, thereby potentially result-
ing in a new social consensus through research 
and education, ultimately enabling the benefits 
of clinical ethics practice for patients and their 
families. Illustrated below are the ways that the 
traditional agents of authority may clash with the 
norms of clinical ethics, particularly in end-of-life 
care situations, which is a topic of wide discussion 
since implementation of the Act. 
(1) Family
In contrast to Western countries, families play a 
crucial role in deciding upon patient treatments 
in many East Asian countries, including Korea. 
Decisions about treatments are often made by 
family members on behalf of competent patients, 
and doctors are often asked not to disclose diag-
noses to patients in terminal stages of illness, due 
to families’ concerns that patients will be psycho-
logically impacted in negative ways. !eoretical 
e"orts have been made to justify such customary 
practices, suggesting the concept of “familial au-
tonomy” in place of the concept of Western in-
dividual autonomy(20). Yet the fact that families 
hold significant power in deciding upon patient 
treatments in East Asian countries does not si-
multaneously nullify the need for, or invalidate 
the concept of individual autonomy. !is is be-
cause East Asian countries, including Korea, are 
now swiftly shifting toward large-scale recogni-
tion of individuals’ rights. Moreover, imposing a 
single dominant tenet of social ideology stands to 
undermine the quality care for diverse patients. 
Indeed, many patients, especially seniors, have 
indicated that they would like to be informed of 
their own diagnoses directly from doctors(21). 
!erefore, intentionally not informing patients 
of the status of their own health based on the re-
quest of patients’ families and/or communicating 
only with patients’ families about decisions on 
treatments are behaviors that are becoming in-
creasingly unacceptable.  
plines of biomedical ethics, is most closely related 
to the ways that people live their lives. Indeed, 
such a fundamental collision could pose challeng-
es for clinical ethics in practice. 
Nevertheless, in consideration of how research 
ethics has successfully been put into practice in 
Korea over the past ten years, one might assume 
that clinical ethics would simply replicate that 
success. !is, however, is a highly optimistic view. 
It cannot be assumed that the successful establish-
ment of IRB systems in hospitals and universities 
ensures the successful establishment of hospital 
ethics committees or healthcare institution eth-
ics committees in the future. !is is because the 
history of patient care goes far beyond the his-
tory of clinical trials or human-subject research. 
Undoubtedly, patient care is more closely linked 
to our lives than research. In fact, patient care 
activities existed most extensively long before 
the framework of biomedical ethics came along. 
!erefore, certain customary practices, regula-
tions, and power structures are already deeply 
rooted within such activities. As a result, norms 
in clinical ethics are much harder to standardize 
internationally than norms in research ethics. In 
other words, the likelihood of a clash between 
systemized norms in imported disciplines and 
existing norms in a society is much greater in 
the field of clinical ethics than in the field of re-
search ethics. To illustrate the challenges facing 
successful implementation of the practice of clin-
ical ethics in Korea, this paper further investigates 
how the three main agents of unquestioned au-
thority in Korean medicine stand to clash with 
the norms of clinical ethics as widely accepted in 
preexisting discussions of bioethics. !e author-
ity of these three main agents– family, govern-
ment, and medical professionals—often clashes 
with a concept of democracy, which is a valued 
prerequisite of biomedical ethics, an imported 
discipline. In fact, the granting of unwavering au-
thority to three agents is not necessarily the result 
of an extensive process of validation, nor is it the 
most appropriate arrangement for addressing the 
challenges that occur in the practice of medicine. 
!erefore, not only does the status quo need not 
be blindly accepted, its acceptance based on tra-
dition alone may not be justified. Nonetheless, in 
order for biomedical ethics to flourish, and for 
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deaths. Aiding and abetting suicide is regarded as 
a criminal o"ense(24). In the context of health-
care, many medical professionals fear accusations 
of aiding and abetting suicide or aiding a murder 
due to the withdrawal of life-sustaining treat-
ments according to patients’ will insofar as this 
type of medical intervention eventually results in 
patients’ death. Consequently, this fear has con-
tributed to the tendency of doctors to over-treat 
patients in end-of-life stages. In previous court 
cases about treatment decisions that have directly 
impacted patients’ lives, rulings have shown that 
patients’ expressed intentions before he or she be-
came incompetent must be verified and that pa-
tients must be in an irreversible death stage(12). 
Legal rulings have emphasized that the judgment 
of patients’ conditions must be made in the most 
cautious manner possible. In other words, the 
right to make a judgment on a patient’s condition 
has not been ceded to medical professionals, and 
instead remained in the hands of judicial authori-
ties(25) prior to the legislation of the Act. 
Such a conservative stance by the government is 
still reflected in the Act, thereby posing potential 
challenges to the practice of clinical ethics, even 
though the Act acknowledges the authority of 
medical professionals to judge whether a patient 
is in an irreversible state. It is worth our scrutiny 
that every article in the Act pertaining to decisions 
on life-sustaining treatment addresses the matter 
with regard to the specific period of time when a 
patient has entered the end-of-life process only. 
As previously mentioned, the end-of-life process, 
as defined by the law, refers to a stage much closer 
to the patient’s coming death in comparison to 
the terminal stage of a patient’s illness. !erefore, 
“end of life” is a significantly short span of time. 
Problems arise in that the Act specifies the duty of 
a healthcare institution ethics committee to pro-
vide guidance in determination of life-sustaining 
treatment, particularly life-sustaining treatment 
at patients’ end of life, thereby limiting the scope 
of activities by ethics committees. While it is true 
that each individual ethics committee may take 
measures to autonomously extend their sphere 
of duties, the majority of medical institutions are 
likely to fail to take such a proactive approach, 
implementing only the bare minimum required 
by the law. Nevertheless, numerous ethical issues 
Another possible factor that may pose a challenge 
to nascent clinical ethics practice due to imple-
mentation of the Act is an unwelcoming attitude 
of families towards HECs or consultation services. 
It has long been accepted that decisions on patient 
treatments are matters that fall strictly under the 
category of “family issues” or personal business, 
precluding the intervention of any outsider. Such 
categorization, however, may eliminate any possi-
bility for medical experts, HECs, and consultants 
to step into the decision-making process in order 
to best serve the interests of patients who have be-
come incompetent. If families are seen as “single 
units” for the making of certain decisions for pa-
tients at the end of life instead of a composition of 
individual family members, opinions of individ-
ual family members as well as their existence will 
naturally be disregarded. Subsequently, the prac-
tice of clinical ethics will struggle to step into the 
decision-making process, as clinical ethics prac-
tice aims to facilitate communication between 
members of the family and help them make the 
best decisions based on medical facts. Below is an 
example of how a specific article of the Act, when 
applied to a real situation, may raise such issues. 
Article 18 of the Act(1) states that the decision 
to withdraw or withhold life-sustaining treatment 
can be made by the patient’s family on behalf of 
the patient, if all members of the patient’s family 
reach unanimous agreement. However, the article 
does not indicate what matters family members 
must unanimously agree upon, and by what cri-
teria agreement must be reached. In bioethics lit-
erature, the widely accepted criterion is “the best 
interest of a patient” in cases wherein it is impos-
sible to verify a patient’s intentions for their own 
life-sustaining treatment(22,23). !us, as a part 
of clinical ethics practice, an HEC or individu-
al consultants could elucidate such criterion for 
patients’ families, thereby facilitating pertinent 
discussions among family members. However, if 
clinical ethics practitioners are blocked outright 
from decision-making processes due to patient 
treatment being regarded as a “family issue,” then 
the experts will not be able to provide the neces-
sary help to patients and their families.  
(2) Government
!e government of South Korea takes a pater-
nalistic approach to matters of people’s lives and 
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In this context, does implementation of the Act 
compel medical professionals to realize their lim-
ited authority and recognize the need for clinical 
ethics practice? In other words, going forward, 
will doctors be inclined to turn to help from eth-
ics committees or ethics consultants if they are 
required to make certain decisions on treatments? 
Taking into account the extent to which doctors 
believe that they were properly addressing similar 
issues before the Act based on their professional 
discernment, this might not be the case. As dis-
cussed above, the scope of legally prescribed activ-
ities for healthcare institution ethics committees 
is very limited. Not only that, matters related to 
the determination of life-sustaining treatment are 
stipulated in detail by the law, with requirement 
that expectations are met or otherwise punish-
able, so as to avoid further discussion or delib-
eration that may lead to the making of nuanced 
ethical judgment about patients’ lives. Under 
these conditions, unless an individual medical 
professional is keenly interested in developing 
treatment plans that best serve a patient’s inter-
est—thereby requesting the help of a committee 
out of good will— there are not likely to be many 
cases where clinical medical professionals ask for 
help. Ultimately, medical professionals willing to 
advocate for patients are what a system of clinical 
ethics is looking to foster, and it is these medi-
cal professionals that any form of clinical ethics 
practice aims to support. !e fact must be consid-
ered, however, that many medical professionals, 
at least during the nascent stages of clinical ethics 
practice, might not agree with the e"ectiveness 
and need for the practice of clinical ethics. From 
this standpoint it is clear that any form of clinical 
ethics practice needs to endeavor consistently and 
cleverly to overcome such obstacles.
Conclusion
Family, government, and medical professionals 
have the potential to pose realistic di#culties in 
successful implementation of the practice of clin-
ical ethics. !is is because the practice of clinical 
ethics will challenge the established roles and au-
thority of these three agents in Korea’s traditional 
social paradigm. However, there is no need for 
healthcare systems and patients to hopelessly ac-
cept the status quo. Implementation of the Act 
on Decisions on Life-Sustaining Treatment for 
can arise in patient care before patients reach their 
end-of-life stages. For instance, if a patient diag-
nosed with a terminal illness were to ask a doc-
tor to withhold life-sustaining treatment, several 
questions would arise: should the doctor refuse to 
withhold the patient’s life-sustaining treatment? 
What kind of communication should the doctor 
initiate and with whom among the parties con-
cerned, including patients and patients’ relatives? 
What ethical and legal issues need to be consid-
ered? !ese are all highly nuanced questions, the 
proper addressing of which requires the practice 
of clinical ethics to help all the involved medi-
cal professionals together with patients and their 
families. However, insofar as the Act stipulates 
that ethics committees deal with ethical issues 
arising at patients’ end of life only, the law may 
fail to facilitate discussions under such circum-
stances. What is more, the law e"ectively prevents 
these discussions from taking place unless the pa-
tient has entered the timeframe specified by the 
Act. 
(3) Medical professionals
Regarding the authority of medical profession-
als, the Act stands to incite a delicate situation 
in terms of power dynamics. Medical profes-
sionals in Korea have assumed authority, just as 
Western medical professionals have, which has 
led to the rise of medical paternalism in Korea. 
As in other countries, the assumed authority of 
doctors is executed under close coordination 
with other authorities, which, in the case of Ko-
rea, are family and government. In other words, 
medical professionals use their power to decide 
upon patient treatments within the boundar-
ies permitted by the government and patients’ 
families. Regrettably, patients are often excluded 
from decision-making processes about their own 
treatments. On the other hand, implementation 
of the Act has resulted in some restriction of the 
authority and freedom of medical professionals, 
which was heretofore unfettered on the matter of 
treatment decisions. Previously, treatment could 
be withheld or withdrawn with the consent of a 
patient’s family (or even a few family members), 
but now such practices have become impossible 
due to certain legal requirements around with-
holding life-sustaining treatment for patients.
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tated by the new law, these changes will eventu-
ally drive the practice of clinical ethics to flourish 
in Korea. Nevertheless, because such success will 
only be possible by way of conflict and resolution 
within the current social order, a keen recogni-
tion of the existing challenges and opportunities 
is necessary for advancement going forward.  
Patients in Hospice and Palliative Care or at the 
End of Life in Korea has brought clear changes 
to the present situation. People are becoming in-
creasingly aware of their rights to self-determina-
tion at the end of life. More people are looking 
for di"erent types of end-of-life care to better 
align with their systems of values, and are actively 
asking to realize these alternative options. Facili-
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